<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720473</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-002493</org_study_id>
    <nct_id>NCT00720473</nct_id>
  </id_info>
  <brief_title>Lamotrigine Therapy in Geriatric Bipolar Depression</brief_title>
  <official_title>Lamotrigine Therapy in the Treatment of Geriatric Bipolar Depression: An Evaluation of Markers of Cerebral Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to study the efficacy and tolerability of lamotrigine in the treatment of older
      adults with bipolar depression and to compare measures of brain energy metabolism between
      older subjects with bipolar depression and healthy age-matched controls in order to better
      understand treatment response in geriatric bipolar depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will use MRI techniques and neuropsychological testing to investigate potential markers of
      treatment response in elderly bipolar depressed patients receiving lamotrigine and
      age-matched, non-depressed controls.

      We intend to test these hypotheses:

        1. At least 50% of older subjects with bipolar depression will respond treatment with
           lamotrigine as evidenced by a 50% reduction on the Montgomery Asberg Rating Scale
           (MADRS). In addition, treatment with lamotrigine will be safe and well tolerated as
           evidenced by a drop-out rate of less than 10% due to adverse effects.

        2. Compared with healthy age-matched, non-demented, non-depressed controls, subjects with
           geriatric bipolar depression will demonstrate abnormalities in cerebral energy
           metabolism as assessed by elevated levels of glutamate and lactate, and decreased levels
           of NAA, using 1H MRS at 4T.

        3. Successful treatment with lamotrigine in geriatric bipolar depression will result in
           decreases in lactate and glutamate, and elevations in NAA.

        4. Baseline measures of executive functioning and information processing speed (measured by
           performance on the Wisconsin Card Sorting Test (WCST), Trails A and B and Stroop tests)
           will be impaired in subjects with geriatric bipolar depression compared with healthy
           controls. These measures will improve with successful treatment with lamotrigine and
           correlate with improvements in markers of cerebral energy metabolism (lactate,
           glutamate, NAA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Glutamine to Creatine Ratio by Diagnosis at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Glutamate to Creatine Ratio by Diagnosis at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean N-Acetyl Aspartate (NAA) to Creatine Ratio by Diagnosis at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Associations Between Depression Symptom Severity and Glutamate to Creatine Ratio at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Estimated changes in least squares mean in the metabolite ratio per 10-point increase in MADRS score. The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Change in Least Squares Mean in Glutamate to Creatine Ratio Between Baseline and Follow-up</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Change in Least Squares Mean in the Glutamine to Creatine Ratio Between Baseline and Follow-up</measure>
    <time_frame>8 weeks</time_frame>
    <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Change in Least Squares Mean in the NAA to Creatine Ratio Between Baseline and Follow-up</measure>
    <time_frame>8 weeks</time_frame>
    <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of MADRS Changes With Glutamate to Creatine Ratio Changes From Baseline to Follow-up</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. The MADRS minimum score is 0 and maximum is 60, with 60 being the most depressed score. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Associations of MADRS Changes With Glutamine to Creatine Ratio Changes From Baseline to Follow-up</measure>
    <time_frame>8 weeks</time_frame>
    <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. MADRS minimum score is 0 and maximum is 60, with 60 being most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Associations of MADRS Changes With NAA to Creatine Ratio Changes From Baseline to Follow-up</measure>
    <time_frame>8 weeks</time_frame>
    <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. MADRS minimum score is 0 and maximum is 60, with 60 being most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Montgomery Asberg Depression Rating Scale (MADRS) Score at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Means of MADRS Scores at 8 Weeks</measure>
    <time_frame>8 Weeks</time_frame>
    <description>The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>A: Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open Label Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Healthy Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
    <arm_group_label>A: Other</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for Bipolar Subjects):

          -  60 years or older

          -  Meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed

          -  First episode of mania before the age of 50 (early-onset bipolar disorder)

          -  Montgomery-Asberg Depression Rating Scale (MADRS) Score of greater or equal to 20.

          -  Young Mania Rating Scale (YMRS) of less than or equal to 6.

          -  Able to provide informed consent

          -  Must speak English

          -  Must be able to visit McLean Hospital for the screening visit and six study visits
             during the 8-week duration of the study.

          -  Subjects may be taking other medications for bipolar depression including
             antidepressants, mood stabilizers and antipsychotic mediations prior to lamotrigine
             therapy, but may not have any dosage adjustments of these medications in the week
             before lamotrigine is added.

        Exclusion Criteria (for Bipolar Subjects):

          -  Serious or unstable medical illness, including cardiovascular, hepatic, renal,
             respiratory, endocrine, neurologic or hematologic disease.

          -  History of seizure disorder

          -  History or current diagnosis of the following psychiatric illnesses: any organic
             mental disorder (including dementia), schizophrenia, schizoaffective disorder,
             delusional disorder, psychotic disorder not otherwise specified, unipolar major
             depressive disorder, patients with substance dependence disorders, including alcohol,
             active within the last 12 months.

          -  First episode of mania after the age of 50 (to exclude late-onset bipolar disorder)

          -  History of multiple adverse drug reactions or allergy to the study drugs.

          -  Use of medications that are excluded in this study (benzodiazepines, barbiturates;
             however, the use of non-benzodiazepine sedative hypnotics (such as zolpidem (Ambien))
             may be used as needed except within 48 hours of the MRI scan)

          -  Any of the exclusion criteria mentioned in the MRI risks section below

        Inclusion Criteria (for Controls):

          -  60 years or older

          -  Able to provide informed consent

          -  Must speak English

          -  Women entering this study must be post-menopausal

        Exclusion Criteria (for Controls):

        - Same criteria for the Bipolar Depressed group with the exception of the &quot;first episode of
        mania&quot; which is not applicable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent P Forester, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <results_first_submitted>November 26, 2013</results_first_submitted>
  <results_first_submitted_qc>June 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2016</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Brent Forester</investigator_full_name>
    <investigator_title>Director, Mood Disorders Division, Geriatric Psychiatry Research Program</investigator_title>
  </responsible_party>
  <keyword>Bipolar depression</keyword>
  <keyword>Elderly</keyword>
  <keyword>Lamotrigine</keyword>
  <keyword>Brain energy metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A: BPD Subjects</title>
          <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
        </group>
        <group group_id="P2">
          <title>B: Healthy Control</title>
          <description>No Intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline scans were available for 37 participants, 23 BPD subjects and 14 for healthy controls. One participant had missing scan data, and twenty one participants with a BPD diagnosis had baseline MADRS scores available.</population>
      <group_list>
        <group group_id="B1">
          <title>BPD Subjects</title>
          <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
        </group>
        <group group_id="B2">
          <title>Control Subjects</title>
          <description>Age matched controls without BPD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="5.9"/>
                    <measurement group_id="B2" value="67.5" spread="8.8"/>
                    <measurement group_id="B3" value="64.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Glutamine to Creatine Ratio by Diagnosis at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Baseline scans were available for 37 participants. One participant was missing scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glutamine to Creatine Ratio by Diagnosis at Baseline</title>
          <population>Baseline scans were available for 37 participants. One participant was missing scan data.</population>
          <units>mean serum Glutamine to Creatine ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".34" spread=".12"/>
                    <measurement group_id="O2" value=".36" spread=".18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Glutamate to Creatine Ratio by Diagnosis at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Baseline scans were available for 37 participants. One participant was missing scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glutamate to Creatine Ratio by Diagnosis at Baseline</title>
          <population>Baseline scans were available for 37 participants. One participant was missing scan data.</population>
          <units>mean serum Glutamate to Creatine ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".96" spread=".29"/>
                    <measurement group_id="O2" value=".85" spread=".25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean N-Acetyl Aspartate (NAA) to Creatine Ratio by Diagnosis at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Baseline scans were available for 37 participants. One participant was missing scan data.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean N-Acetyl Aspartate (NAA) to Creatine Ratio by Diagnosis at Baseline</title>
          <population>Baseline scans were available for 37 participants. One participant was missing scan data.</population>
          <units>Mean NAA to creatine ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.14"/>
                    <measurement group_id="O2" value="0.84" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Associations Between Depression Symptom Severity and Glutamate to Creatine Ratio at Baseline</title>
        <description>Estimated changes in least squares mean in the metabolite ratio per 10-point increase in MADRS score. The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
        <time_frame>Baseline</time_frame>
        <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Other</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Associations Between Depression Symptom Severity and Glutamate to Creatine Ratio at Baseline</title>
          <description>Estimated changes in least squares mean in the metabolite ratio per 10-point increase in MADRS score. The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
          <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
          <units>Glu:Cr/+10 MADRS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="-0.02" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated Change in Least Squares Mean in Glutamate to Creatine Ratio Between Baseline and Follow-up</title>
        <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
        <time_frame>8 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Change in Least Squares Mean in Glutamate to Creatine Ratio Between Baseline and Follow-up</title>
          <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
          <units>serum Glutamate to Creatine ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.17" upper_limit="0.16"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.30" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated Change in Least Squares Mean in the Glutamine to Creatine Ratio Between Baseline and Follow-up</title>
        <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Change in Least Squares Mean in the Glutamine to Creatine Ratio Between Baseline and Follow-up</title>
          <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
          <units>serum Glutamine to Creatine ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.09" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-0.05" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated Change in Least Squares Mean in the NAA to Creatine Ratio Between Baseline and Follow-up</title>
        <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Change in Least Squares Mean in the NAA to Creatine Ratio Between Baseline and Follow-up</title>
          <description>Follow-up Least Squares Mean - Baseline Least Squares Mean</description>
          <units>NAA to creatine ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.06" upper_limit="0.19"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.16" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Association of MADRS Changes With Glutamate to Creatine Ratio Changes From Baseline to Follow-up</title>
        <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. The MADRS minimum score is 0 and maximum is 60, with 60 being the most depressed score. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
        <time_frame>8 Weeks</time_frame>
        <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Association of MADRS Changes With Glutamate to Creatine Ratio Changes From Baseline to Follow-up</title>
          <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. The MADRS minimum score is 0 and maximum is 60, with 60 being the most depressed score. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
          <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
          <units>Glu:Cr/-10 MADRS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.007" lower_limit="-0.24" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Associations of MADRS Changes With Glutamine to Creatine Ratio Changes From Baseline to Follow-up</title>
        <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. MADRS minimum score is 0 and maximum is 60, with 60 being most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
        <time_frame>8 weeks</time_frame>
        <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Associations of MADRS Changes With Glutamine to Creatine Ratio Changes From Baseline to Follow-up</title>
          <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. MADRS minimum score is 0 and maximum is 60, with 60 being most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
          <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
          <units>Gln:Cr/-10 MADRS Score</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.07" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Associations of MADRS Changes With NAA to Creatine Ratio Changes From Baseline to Follow-up</title>
        <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. MADRS minimum score is 0 and maximum is 60, with 60 being most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
        <time_frame>8 weeks</time_frame>
        <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Associations of MADRS Changes With NAA to Creatine Ratio Changes From Baseline to Follow-up</title>
          <description>Estimated least squares mean metabolite ratio changes with a 10-point decrease in MADRS score. MADRS minimum score is 0 and maximum is 60, with 60 being most depressed. Estimate was from linear regression models controlling for age and sex. The change is across regions, parieto-occipital and anterior cingulate cortex.</description>
          <population>Association between depression symptom severity and metabolite ratios were only conducted in the depressed group, because there should be no change in MADRS score for non-depressed control subjects who received no treatment.</population>
          <units>NAA:Cr/-10 MADRS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.04" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Montgomery Asberg Depression Rating Scale (MADRS) Score at Baseline</title>
        <description>The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed.</description>
        <time_frame>Baseline</time_frame>
        <population>MADRS scores were available for 27 eligible bipolar subjects and 14 eligible controls.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Montgomery Asberg Depression Rating Scale (MADRS) Score at Baseline</title>
          <description>The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed.</description>
          <population>MADRS scores were available for 27 eligible bipolar subjects and 14 eligible controls.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.78" spread="6.65"/>
                    <measurement group_id="O2" value="1.03" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Means of MADRS Scores at 8 Weeks</title>
        <description>The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed.</description>
        <time_frame>8 Weeks</time_frame>
        <population>MADRS scores were available for 16 bipolar subjects who completed the protocol and 8 healthy controls.</population>
        <group_list>
          <group group_id="O1">
            <title>BPD Subjects</title>
            <description>Open Label Study
Lamotrigine : Lamotrigine with dosage range from 25 mg to 200 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age matched controls without BPD</description>
          </group>
        </group_list>
        <measure>
          <title>Means of MADRS Scores at 8 Weeks</title>
          <description>The minimum MADRS score is 0 and the maximum is 60, with 60 being the most depressed.</description>
          <population>MADRS scores were available for 16 bipolar subjects who completed the protocol and 8 healthy controls.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.31" spread="9.41"/>
                    <measurement group_id="O2" value="1.38" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Subjects</title>
          <description>Age matched controls without BPD</description>
        </group>
        <group group_id="E2">
          <title>BPD Subjects</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <description>Subject fell off bicycle and lost consciousness.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <description>Subject was hospitalized due to mania</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <description>Subject reported blurry vision</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach upset</sub_title>
                <description>Two subject reported gastrointestinal problems including upset stomach and indigestion.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased balance</sub_title>
                <description>Three subjects reported feeling unbalanced or dizzy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Two subjects reported mild headaches.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>A subject reported gaining one pound.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mania</sub_title>
                <description>Subject entered a manic state, with decreased sleep, pressured speech, and delusions.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Four subjects reported sleep disturbances.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>One subject experienced increased irritability</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Runny Nose</sub_title>
                <description>One subject reported a mild runny nose.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Subject developed a rash, which was found to be unrelated by the subject's dermatologist.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Subject developed a rash after taking second dose.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <description>Subject reported developing a blister on the hand.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited data was available for associating changes in MADRS scores with metabolite changes (22 regions from 11 participants with BPD).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brent Forester</name_or_title>
      <organization>McLean Hospital</organization>
      <phone>(617) 855-3622</phone>
      <email>bforester@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

